Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study
Objectives To compare visual outcomes for low vision eyes (LVE) (20/200 Snellen) at the time of the first injection in a clinical practice setting. Methods Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with a...
Gespeichert in:
| Veröffentlicht in: | Eye (London) 2024-12, Vol.38 (18), p.3450-3458 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 3458 |
|---|---|
| container_issue | 18 |
| container_start_page | 3450 |
| container_title | Eye (London) |
| container_volume | 38 |
| creator | Puzo, Martín Calvo-Perez, Pilar Bartol-Puyal, Francisco Sanchez-Monroy, Jorge Martin-Pinardel, Ruben Parrado-Carrillo, Alba Moll-Udina, Aina Bernal-Morales, Carolina Sanchez-Vela, Laura Sararols-Ramsay, Laura Garay-Aramburu, Gonzaga Arruabarrena, Carolina García-Arumí, José Abraldes, Maximino Ruiz-Moreno, José María Valldeperas, Xavier Velázquez-Villoria, Daniel Escobar-Barranco, José Juan Gallego-Pinazo, Roberto Figueroa, Marta S. Figueras-Roca, Marc Barthelmes, Daniel Gillies, Mark C. Casaroli-Marano, Ricardo P. Zarranz-Ventura, Javier |
| description | Objectives
To compare visual outcomes for low vision eyes (LVE) (20/200 Snellen) at the time of the first injection in a clinical practice setting.
Methods
Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!).
Results
3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (
p
|
| doi_str_mv | 10.1038/s41433-024-03322-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3107784430</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3141254422</sourcerecordid><originalsourceid>FETCH-LOGICAL-c256t-de727606f22b0fecbbc1c2212987fcd1b07dec75efd5557400c7d170738344e83</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0EokPhBVggS2zYZPAtcYbdUNGLVBXERWIXOfZJxlViD7bT0TwjL1VP0xaJRVc-8v-d_5yjH6G3lCwp4fXHKKjgvCBMFIRzxor6GVpQIauiFKV4jhZkVZKCMfb7CL2K8ZqQLEryEh3xFSdVRasF-ntq-03C3yFZpwb8ebDOOIgR__i2vrhaZmHrQ8L8E9ZZsjozfkrajxCx7_CNinoaVMDgjE8bGGwG-uB3aYM7pZMP2LqNbW2uYi7x4Hf4xkbrHYZ99tjZTDrwj0aqhyLAoBIYPKr5z0APDoJKuW2J19jdVXmSUUm1KgKOaTL71-hFp4YIb-7fY_Tr9MvPk_Pi8uvZxcn6stCsrFJhQDJZkapjrCUd6LbVVDNG2aqWnTa0JdKAliV0pixLKQjR0lBJJK-5EFDzY_Rh9t0G_2eCmJrRRg3DoPIhU2w4JVLWQnCS0ff_odd-Cnn1AyUoK4VgLFNspnTwMQbomm2wowr7hpLmEHUzR93kqJu7qJvDFu_urad2BPPY8pBtBvgMxCy5HsK_2U_Y3gIGm7fE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3141254422</pqid></control><display><type>article</type><title>Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Puzo, Martín ; Calvo-Perez, Pilar ; Bartol-Puyal, Francisco ; Sanchez-Monroy, Jorge ; Martin-Pinardel, Ruben ; Parrado-Carrillo, Alba ; Moll-Udina, Aina ; Bernal-Morales, Carolina ; Sanchez-Vela, Laura ; Sararols-Ramsay, Laura ; Garay-Aramburu, Gonzaga ; Arruabarrena, Carolina ; García-Arumí, José ; Abraldes, Maximino ; Ruiz-Moreno, José María ; Valldeperas, Xavier ; Velázquez-Villoria, Daniel ; Escobar-Barranco, José Juan ; Gallego-Pinazo, Roberto ; Figueroa, Marta S. ; Figueras-Roca, Marc ; Barthelmes, Daniel ; Gillies, Mark C. ; Casaroli-Marano, Ricardo P. ; Zarranz-Ventura, Javier</creator><creatorcontrib>Puzo, Martín ; Calvo-Perez, Pilar ; Bartol-Puyal, Francisco ; Sanchez-Monroy, Jorge ; Martin-Pinardel, Ruben ; Parrado-Carrillo, Alba ; Moll-Udina, Aina ; Bernal-Morales, Carolina ; Sanchez-Vela, Laura ; Sararols-Ramsay, Laura ; Garay-Aramburu, Gonzaga ; Arruabarrena, Carolina ; García-Arumí, José ; Abraldes, Maximino ; Ruiz-Moreno, José María ; Valldeperas, Xavier ; Velázquez-Villoria, Daniel ; Escobar-Barranco, José Juan ; Gallego-Pinazo, Roberto ; Figueroa, Marta S. ; Figueras-Roca, Marc ; Barthelmes, Daniel ; Gillies, Mark C. ; Casaroli-Marano, Ricardo P. ; Zarranz-Ventura, Javier ; from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group</creatorcontrib><description>Objectives
To compare visual outcomes for low vision eyes (LVE) (<35 letters LogMAR or <20/200 Snellen) versus non-low vision eyes (NLVE) (>35 letters LogMAR or >20/200 Snellen) at the time of the first injection in a clinical practice setting.
Methods
Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!).
Results
3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (
p
< 0.001), at 12, 24, and 36 months (+15, +15, and +13 letters respectively). The proportion of patients with VA loss (−5 letters) differed between groups at 12, 24, and 36 and was significantly greater (
p
< 0.001) in NLVE. The proportion of patients with VA gain (+5 letters) was significantly higher (
p
< 0.001) in LVE in all timeframes. The proportions of LVE that still had VA ≤ 35 letters at 12, 24, and 36 months were 54%, 54%, and 57%. Conversely, 8%, 9%, and 8% of LVE achieved VA ≥ 70 letters at 12, 24, and 36 months. LVE received fewer intravitreal injections than NLVE throughout follow-up (6, 9, 12 vs 7, 11, 15).
Conclusion
Findings of this study support the need for ongoing therapy in patients with initial visual acuity less than 35 letters since sustained visual improvements can be achieved and maintained for the first 3 years of treatment.</description><identifier>ISSN: 0950-222X</identifier><identifier>ISSN: 1476-5454</identifier><identifier>EISSN: 1476-5454</identifier><identifier>DOI: 10.1038/s41433-024-03322-8</identifier><identifier>PMID: 39306616</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject><![CDATA[692/308/409 ; 692/699/3161/3175 ; Acuity ; Age ; Aged ; Aged, 80 and over ; Angiogenesis Inhibitors - administration & dosage ; Angiogenesis Inhibitors - therapeutic use ; Bevacizumab - administration & dosage ; Bevacizumab - therapeutic use ; Blindness ; Databases, Factual ; Eye ; Female ; Humans ; Intravitreal Injections ; Laboratory Medicine ; Macular degeneration ; Male ; Medicine ; Medicine & Public Health ; Ophthalmology ; Patients ; Pharmaceutical Sciences/Technology ; Ranibizumab - administration & dosage ; Ranibizumab - therapeutic use ; Receptors, Vascular Endothelial Growth Factor - administration & dosage ; Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors ; Receptors, Vascular Endothelial Growth Factor - therapeutic use ; Retina ; Retrospective Studies ; Spain ; Surgery ; Surgical Oncology ; Treatment Outcome ; Vascular endothelial growth factor ; Vascular Endothelial Growth Factor A - antagonists & inhibitors ; Vision ; Vision, Low - physiopathology ; Visual acuity ; Visual Acuity - physiology ; Wet Macular Degeneration - drug therapy ; Wet Macular Degeneration - physiopathology]]></subject><ispartof>Eye (London), 2024-12, Vol.38 (18), p.3450-3458</ispartof><rights>The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2024 Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.</rights><rights>Copyright Nature Publishing Group Dec 2024</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c256t-de727606f22b0fecbbc1c2212987fcd1b07dec75efd5557400c7d170738344e83</cites><orcidid>0000-0002-5048-4846 ; 0000-0001-5743-1520 ; 0000-0001-8580-0274 ; 0000-0001-5469-3963 ; 0000-0002-8677-6859 ; 0000-0003-2338-8143 ; 0000-0002-5312-8900 ; 0000-0001-5255-8426 ; 0000-0002-4476-6003 ; 0000-0001-9636-0788</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41433-024-03322-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41433-024-03322-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39306616$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Puzo, Martín</creatorcontrib><creatorcontrib>Calvo-Perez, Pilar</creatorcontrib><creatorcontrib>Bartol-Puyal, Francisco</creatorcontrib><creatorcontrib>Sanchez-Monroy, Jorge</creatorcontrib><creatorcontrib>Martin-Pinardel, Ruben</creatorcontrib><creatorcontrib>Parrado-Carrillo, Alba</creatorcontrib><creatorcontrib>Moll-Udina, Aina</creatorcontrib><creatorcontrib>Bernal-Morales, Carolina</creatorcontrib><creatorcontrib>Sanchez-Vela, Laura</creatorcontrib><creatorcontrib>Sararols-Ramsay, Laura</creatorcontrib><creatorcontrib>Garay-Aramburu, Gonzaga</creatorcontrib><creatorcontrib>Arruabarrena, Carolina</creatorcontrib><creatorcontrib>García-Arumí, José</creatorcontrib><creatorcontrib>Abraldes, Maximino</creatorcontrib><creatorcontrib>Ruiz-Moreno, José María</creatorcontrib><creatorcontrib>Valldeperas, Xavier</creatorcontrib><creatorcontrib>Velázquez-Villoria, Daniel</creatorcontrib><creatorcontrib>Escobar-Barranco, José Juan</creatorcontrib><creatorcontrib>Gallego-Pinazo, Roberto</creatorcontrib><creatorcontrib>Figueroa, Marta S.</creatorcontrib><creatorcontrib>Figueras-Roca, Marc</creatorcontrib><creatorcontrib>Barthelmes, Daniel</creatorcontrib><creatorcontrib>Gillies, Mark C.</creatorcontrib><creatorcontrib>Casaroli-Marano, Ricardo P.</creatorcontrib><creatorcontrib>Zarranz-Ventura, Javier</creatorcontrib><creatorcontrib>from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group</creatorcontrib><title>Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study</title><title>Eye (London)</title><addtitle>Eye</addtitle><addtitle>Eye (Lond)</addtitle><description>Objectives
To compare visual outcomes for low vision eyes (LVE) (<35 letters LogMAR or <20/200 Snellen) versus non-low vision eyes (NLVE) (>35 letters LogMAR or >20/200 Snellen) at the time of the first injection in a clinical practice setting.
Methods
Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!).
Results
3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (
p
< 0.001), at 12, 24, and 36 months (+15, +15, and +13 letters respectively). The proportion of patients with VA loss (−5 letters) differed between groups at 12, 24, and 36 and was significantly greater (
p
< 0.001) in NLVE. The proportion of patients with VA gain (+5 letters) was significantly higher (
p
< 0.001) in LVE in all timeframes. The proportions of LVE that still had VA ≤ 35 letters at 12, 24, and 36 months were 54%, 54%, and 57%. Conversely, 8%, 9%, and 8% of LVE achieved VA ≥ 70 letters at 12, 24, and 36 months. LVE received fewer intravitreal injections than NLVE throughout follow-up (6, 9, 12 vs 7, 11, 15).
Conclusion
Findings of this study support the need for ongoing therapy in patients with initial visual acuity less than 35 letters since sustained visual improvements can be achieved and maintained for the first 3 years of treatment.</description><subject>692/308/409</subject><subject>692/699/3161/3175</subject><subject>Acuity</subject><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Angiogenesis Inhibitors - administration & dosage</subject><subject>Angiogenesis Inhibitors - therapeutic use</subject><subject>Bevacizumab - administration & dosage</subject><subject>Bevacizumab - therapeutic use</subject><subject>Blindness</subject><subject>Databases, Factual</subject><subject>Eye</subject><subject>Female</subject><subject>Humans</subject><subject>Intravitreal Injections</subject><subject>Laboratory Medicine</subject><subject>Macular degeneration</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Ophthalmology</subject><subject>Patients</subject><subject>Pharmaceutical Sciences/Technology</subject><subject>Ranibizumab - administration & dosage</subject><subject>Ranibizumab - therapeutic use</subject><subject>Receptors, Vascular Endothelial Growth Factor - administration & dosage</subject><subject>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</subject><subject>Receptors, Vascular Endothelial Growth Factor - therapeutic use</subject><subject>Retina</subject><subject>Retrospective Studies</subject><subject>Spain</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Treatment Outcome</subject><subject>Vascular endothelial growth factor</subject><subject>Vascular Endothelial Growth Factor A - antagonists & inhibitors</subject><subject>Vision</subject><subject>Vision, Low - physiopathology</subject><subject>Visual acuity</subject><subject>Visual Acuity - physiology</subject><subject>Wet Macular Degeneration - drug therapy</subject><subject>Wet Macular Degeneration - physiopathology</subject><issn>0950-222X</issn><issn>1476-5454</issn><issn>1476-5454</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu1DAUhi0EokPhBVggS2zYZPAtcYbdUNGLVBXERWIXOfZJxlViD7bT0TwjL1VP0xaJRVc-8v-d_5yjH6G3lCwp4fXHKKjgvCBMFIRzxor6GVpQIauiFKV4jhZkVZKCMfb7CL2K8ZqQLEryEh3xFSdVRasF-ntq-03C3yFZpwb8ebDOOIgR__i2vrhaZmHrQ8L8E9ZZsjozfkrajxCx7_CNinoaVMDgjE8bGGwG-uB3aYM7pZMP2LqNbW2uYi7x4Hf4xkbrHYZ99tjZTDrwj0aqhyLAoBIYPKr5z0APDoJKuW2J19jdVXmSUUm1KgKOaTL71-hFp4YIb-7fY_Tr9MvPk_Pi8uvZxcn6stCsrFJhQDJZkapjrCUd6LbVVDNG2aqWnTa0JdKAliV0pixLKQjR0lBJJK-5EFDzY_Rh9t0G_2eCmJrRRg3DoPIhU2w4JVLWQnCS0ff_odd-Cnn1AyUoK4VgLFNspnTwMQbomm2wowr7hpLmEHUzR93kqJu7qJvDFu_urad2BPPY8pBtBvgMxCy5HsK_2U_Y3gIGm7fE</recordid><startdate>20241201</startdate><enddate>20241201</enddate><creator>Puzo, Martín</creator><creator>Calvo-Perez, Pilar</creator><creator>Bartol-Puyal, Francisco</creator><creator>Sanchez-Monroy, Jorge</creator><creator>Martin-Pinardel, Ruben</creator><creator>Parrado-Carrillo, Alba</creator><creator>Moll-Udina, Aina</creator><creator>Bernal-Morales, Carolina</creator><creator>Sanchez-Vela, Laura</creator><creator>Sararols-Ramsay, Laura</creator><creator>Garay-Aramburu, Gonzaga</creator><creator>Arruabarrena, Carolina</creator><creator>García-Arumí, José</creator><creator>Abraldes, Maximino</creator><creator>Ruiz-Moreno, José María</creator><creator>Valldeperas, Xavier</creator><creator>Velázquez-Villoria, Daniel</creator><creator>Escobar-Barranco, José Juan</creator><creator>Gallego-Pinazo, Roberto</creator><creator>Figueroa, Marta S.</creator><creator>Figueras-Roca, Marc</creator><creator>Barthelmes, Daniel</creator><creator>Gillies, Mark C.</creator><creator>Casaroli-Marano, Ricardo P.</creator><creator>Zarranz-Ventura, Javier</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-5048-4846</orcidid><orcidid>https://orcid.org/0000-0001-5743-1520</orcidid><orcidid>https://orcid.org/0000-0001-8580-0274</orcidid><orcidid>https://orcid.org/0000-0001-5469-3963</orcidid><orcidid>https://orcid.org/0000-0002-8677-6859</orcidid><orcidid>https://orcid.org/0000-0003-2338-8143</orcidid><orcidid>https://orcid.org/0000-0002-5312-8900</orcidid><orcidid>https://orcid.org/0000-0001-5255-8426</orcidid><orcidid>https://orcid.org/0000-0002-4476-6003</orcidid><orcidid>https://orcid.org/0000-0001-9636-0788</orcidid></search><sort><creationdate>20241201</creationdate><title>Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study</title><author>Puzo, Martín ; Calvo-Perez, Pilar ; Bartol-Puyal, Francisco ; Sanchez-Monroy, Jorge ; Martin-Pinardel, Ruben ; Parrado-Carrillo, Alba ; Moll-Udina, Aina ; Bernal-Morales, Carolina ; Sanchez-Vela, Laura ; Sararols-Ramsay, Laura ; Garay-Aramburu, Gonzaga ; Arruabarrena, Carolina ; García-Arumí, José ; Abraldes, Maximino ; Ruiz-Moreno, José María ; Valldeperas, Xavier ; Velázquez-Villoria, Daniel ; Escobar-Barranco, José Juan ; Gallego-Pinazo, Roberto ; Figueroa, Marta S. ; Figueras-Roca, Marc ; Barthelmes, Daniel ; Gillies, Mark C. ; Casaroli-Marano, Ricardo P. ; Zarranz-Ventura, Javier</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c256t-de727606f22b0fecbbc1c2212987fcd1b07dec75efd5557400c7d170738344e83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>692/308/409</topic><topic>692/699/3161/3175</topic><topic>Acuity</topic><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Angiogenesis Inhibitors - administration & dosage</topic><topic>Angiogenesis Inhibitors - therapeutic use</topic><topic>Bevacizumab - administration & dosage</topic><topic>Bevacizumab - therapeutic use</topic><topic>Blindness</topic><topic>Databases, Factual</topic><topic>Eye</topic><topic>Female</topic><topic>Humans</topic><topic>Intravitreal Injections</topic><topic>Laboratory Medicine</topic><topic>Macular degeneration</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Ophthalmology</topic><topic>Patients</topic><topic>Pharmaceutical Sciences/Technology</topic><topic>Ranibizumab - administration & dosage</topic><topic>Ranibizumab - therapeutic use</topic><topic>Receptors, Vascular Endothelial Growth Factor - administration & dosage</topic><topic>Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors</topic><topic>Receptors, Vascular Endothelial Growth Factor - therapeutic use</topic><topic>Retina</topic><topic>Retrospective Studies</topic><topic>Spain</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Treatment Outcome</topic><topic>Vascular endothelial growth factor</topic><topic>Vascular Endothelial Growth Factor A - antagonists & inhibitors</topic><topic>Vision</topic><topic>Vision, Low - physiopathology</topic><topic>Visual acuity</topic><topic>Visual Acuity - physiology</topic><topic>Wet Macular Degeneration - drug therapy</topic><topic>Wet Macular Degeneration - physiopathology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Puzo, Martín</creatorcontrib><creatorcontrib>Calvo-Perez, Pilar</creatorcontrib><creatorcontrib>Bartol-Puyal, Francisco</creatorcontrib><creatorcontrib>Sanchez-Monroy, Jorge</creatorcontrib><creatorcontrib>Martin-Pinardel, Ruben</creatorcontrib><creatorcontrib>Parrado-Carrillo, Alba</creatorcontrib><creatorcontrib>Moll-Udina, Aina</creatorcontrib><creatorcontrib>Bernal-Morales, Carolina</creatorcontrib><creatorcontrib>Sanchez-Vela, Laura</creatorcontrib><creatorcontrib>Sararols-Ramsay, Laura</creatorcontrib><creatorcontrib>Garay-Aramburu, Gonzaga</creatorcontrib><creatorcontrib>Arruabarrena, Carolina</creatorcontrib><creatorcontrib>García-Arumí, José</creatorcontrib><creatorcontrib>Abraldes, Maximino</creatorcontrib><creatorcontrib>Ruiz-Moreno, José María</creatorcontrib><creatorcontrib>Valldeperas, Xavier</creatorcontrib><creatorcontrib>Velázquez-Villoria, Daniel</creatorcontrib><creatorcontrib>Escobar-Barranco, José Juan</creatorcontrib><creatorcontrib>Gallego-Pinazo, Roberto</creatorcontrib><creatorcontrib>Figueroa, Marta S.</creatorcontrib><creatorcontrib>Figueras-Roca, Marc</creatorcontrib><creatorcontrib>Barthelmes, Daniel</creatorcontrib><creatorcontrib>Gillies, Mark C.</creatorcontrib><creatorcontrib>Casaroli-Marano, Ricardo P.</creatorcontrib><creatorcontrib>Zarranz-Ventura, Javier</creatorcontrib><creatorcontrib>from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Eye (London)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Puzo, Martín</au><au>Calvo-Perez, Pilar</au><au>Bartol-Puyal, Francisco</au><au>Sanchez-Monroy, Jorge</au><au>Martin-Pinardel, Ruben</au><au>Parrado-Carrillo, Alba</au><au>Moll-Udina, Aina</au><au>Bernal-Morales, Carolina</au><au>Sanchez-Vela, Laura</au><au>Sararols-Ramsay, Laura</au><au>Garay-Aramburu, Gonzaga</au><au>Arruabarrena, Carolina</au><au>García-Arumí, José</au><au>Abraldes, Maximino</au><au>Ruiz-Moreno, José María</au><au>Valldeperas, Xavier</au><au>Velázquez-Villoria, Daniel</au><au>Escobar-Barranco, José Juan</au><au>Gallego-Pinazo, Roberto</au><au>Figueroa, Marta S.</au><au>Figueras-Roca, Marc</au><au>Barthelmes, Daniel</au><au>Gillies, Mark C.</au><au>Casaroli-Marano, Ricardo P.</au><au>Zarranz-Ventura, Javier</au><aucorp>from the writing committee of the Fight Retinal Blindness Spain (FRB! Spain) Users Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study</atitle><jtitle>Eye (London)</jtitle><stitle>Eye</stitle><addtitle>Eye (Lond)</addtitle><date>2024-12-01</date><risdate>2024</risdate><volume>38</volume><issue>18</issue><spage>3450</spage><epage>3458</epage><pages>3450-3458</pages><issn>0950-222X</issn><issn>1476-5454</issn><eissn>1476-5454</eissn><abstract>Objectives
To compare visual outcomes for low vision eyes (LVE) (<35 letters LogMAR or <20/200 Snellen) versus non-low vision eyes (NLVE) (>35 letters LogMAR or >20/200 Snellen) at the time of the first injection in a clinical practice setting.
Methods
Subgroup analysis of a multicenter national database of treatment- naïve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!).
Results
3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (
p
< 0.001), at 12, 24, and 36 months (+15, +15, and +13 letters respectively). The proportion of patients with VA loss (−5 letters) differed between groups at 12, 24, and 36 and was significantly greater (
p
< 0.001) in NLVE. The proportion of patients with VA gain (+5 letters) was significantly higher (
p
< 0.001) in LVE in all timeframes. The proportions of LVE that still had VA ≤ 35 letters at 12, 24, and 36 months were 54%, 54%, and 57%. Conversely, 8%, 9%, and 8% of LVE achieved VA ≥ 70 letters at 12, 24, and 36 months. LVE received fewer intravitreal injections than NLVE throughout follow-up (6, 9, 12 vs 7, 11, 15).
Conclusion
Findings of this study support the need for ongoing therapy in patients with initial visual acuity less than 35 letters since sustained visual improvements can be achieved and maintained for the first 3 years of treatment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>39306616</pmid><doi>10.1038/s41433-024-03322-8</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-5048-4846</orcidid><orcidid>https://orcid.org/0000-0001-5743-1520</orcidid><orcidid>https://orcid.org/0000-0001-8580-0274</orcidid><orcidid>https://orcid.org/0000-0001-5469-3963</orcidid><orcidid>https://orcid.org/0000-0002-8677-6859</orcidid><orcidid>https://orcid.org/0000-0003-2338-8143</orcidid><orcidid>https://orcid.org/0000-0002-5312-8900</orcidid><orcidid>https://orcid.org/0000-0001-5255-8426</orcidid><orcidid>https://orcid.org/0000-0002-4476-6003</orcidid><orcidid>https://orcid.org/0000-0001-9636-0788</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0950-222X |
| ispartof | Eye (London), 2024-12, Vol.38 (18), p.3450-3458 |
| issn | 0950-222X 1476-5454 1476-5454 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3107784430 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | 692/308/409 692/699/3161/3175 Acuity Age Aged Aged, 80 and over Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Bevacizumab - administration & dosage Bevacizumab - therapeutic use Blindness Databases, Factual Eye Female Humans Intravitreal Injections Laboratory Medicine Macular degeneration Male Medicine Medicine & Public Health Ophthalmology Patients Pharmaceutical Sciences/Technology Ranibizumab - administration & dosage Ranibizumab - therapeutic use Receptors, Vascular Endothelial Growth Factor - administration & dosage Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors Receptors, Vascular Endothelial Growth Factor - therapeutic use Retina Retrospective Studies Spain Surgery Surgical Oncology Treatment Outcome Vascular endothelial growth factor Vascular Endothelial Growth Factor A - antagonists & inhibitors Vision Vision, Low - physiopathology Visual acuity Visual Acuity - physiology Wet Macular Degeneration - drug therapy Wet Macular Degeneration - physiopathology |
| title | Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T08%3A51%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fight%20Retinal%20Blindness%20SPAIN.%20Report%203:%20clinical%20outcomes%20of%20vascular%20endothelial%20growth%20factor%20inhibitors%20in%20low%20vision%20eyes%20with%20neovascular%20age-related%20macular%20degeneration.%20A%20national%20database%20study&rft.jtitle=Eye%20(London)&rft.au=Puzo,%20Mart%C3%ADn&rft.aucorp=from%20the%20writing%20committee%20of%20the%20Fight%20Retinal%20Blindness%20Spain%20(FRB!%20Spain)%20Users%20Group&rft.date=2024-12-01&rft.volume=38&rft.issue=18&rft.spage=3450&rft.epage=3458&rft.pages=3450-3458&rft.issn=0950-222X&rft.eissn=1476-5454&rft_id=info:doi/10.1038/s41433-024-03322-8&rft_dat=%3Cproquest_cross%3E3141254422%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3141254422&rft_id=info:pmid/39306616&rfr_iscdi=true |